Would you add ADT to EBRT for favorable intermediate risk patients with T1c prostate cancer by DRE and bilateral prostatic lobe involvement by MRI?
Would gene expression testing (e.g., Decipher, Prolaris, Oncotype DX) guide your management recommendations?